Drugs of abuse testing by tandem mass spectrometry: A rapid, simple method to replace immunoassays

Clinical Biochemistry

Volumn 42, Issue 15, 2009, Pages 1531-1542

  Eichhorst, Jeff C ^a,b   Etter, Michele L ^a,b   Rousseaux, Nadine ^a,b   Lehotay, Denis C ^a,b  

^a Saskatchewan Disease Control Laboratory   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Chromatography; Drugs of abuse; GC MS; Screening; Tandem mass spectrometry; Toxicology; UPLC

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 7 AMINOFLUNITRAZEPAM; ALPRAZOLAM; AMPHETAMINE; AMPHETAMINE DERIVATIVE; CLONAZEPAM; COCAINE; DIAZEPAM; DIPHENHYDRAMINE; FENTANYL; FLUNITRAZEPAM; FLURAZEPAM; HYDROMORPHONE; KETAMINE; LORAZEPAM; LYSERGIDE; METHYLPHENIDATE; MORPHINE; MORPHINE 6 ACETATE; MORPHINE DERIVATIVE; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; NORDAZEPAM; OXAZEPAM; OXYCODONE; PETHIDINE; PSEUDOEPHEDRINE; RITALINIC ACID; TEMAZEPAM; TRIAZOLAM;

ACCURACY; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG ABUSE; HIGH THROUGHPUT SCREENING; HYDROLYSIS; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; PARTICLE SIZE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REFERENCE VALUE; RELIABILITY; TANDEM MASS SPECTROMETRY; ULTRA PRESSURE LIQUID CHROMATOGRAPHY; URINALYSIS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMMUNOASSAY; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY;

EID: 70249127173     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.07.019     Document Type: Article

References (19)

1. Wineker R. Immunoassays Continue to Improve, Expand and Evolve (2008), American Association for Clinical Chemistry, Washington, D.C
2. Smink B.E., Mathijssen M.P., Lusthof K.J., et al. Comparison of urine and oral fluid as matrices for screening of thirty-three benzodiazepines and benzodiazepine-like substances using immunoassay and LC-MS(-MS). J. Anal. Toxicol. 30 (2006) 478-485
3. Pil K., and Verstraete A. Current developments in drug testing in oral fluid. Ther. Drug Monit. 30 (2008) 196-202
4. Mortier K.A., Dams R., Lambert W.E., et al. Determination of paramethoxyamphetamine and other amphetamine-related designer drugs by liquid chromatography/sonic spray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 16 (2002) 865-870
5. Kintz P., Villain M., Concheiro M., and Cirimele V. Screening and confirmatory method for benzodiazepines and hypnotics in oral fluid by LC-MS/MS. Forensic Sci Int 150 (2005) 213-220
6. Fitzgerald R.L., Rivera J.D., and Herold D.A. Broad spectrum drug identification directly from urine, using liquid chromatography-tandem mass spectrometry. Clin. Chem. 45 (1999) t-34
7. Allen K.R., Azad R., Field H.P., and Blake D.K. Replacement of immunoassay by LC tandem mass spectrometry for the routine measurement of drugs of abuse in oral fluid. Ann. Clin. Biochem. 42 (2005) 277-284
8. Maralikova B., and Weinmann W. Confirmatory analysis for drugs of abuse in plasma and urine by high-performance liquid chromatography-tandem mass spectrometry with respect to criteria for compound identification. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 811 (2004) 21-30
9. Tatsuno M., Nishikawa M., Katagi M., and Tsuchihashi H. Simultaneous determination of illicit drugs in human urine by liquid chromatography-mass spectrometry. J. Anal. Toxicol. 20 (1996) 281-286
10. Weinmann W., Vogt S., Goerke R., Muller C., and Bromberger A. Simultaneous determination of THC-COOH and THC-COOH-glucuronide in urine samples by LC/MS/MS. Forensic. Sci. Int. 113 (2000) 381-387
11. Nordgren H.K., and Beck O. Multicomponent screening for drugs of abuse: direct analysis of urine by LC-MS-MS. Ther. Drug Monit. 26 (2004) 90-97
12. Jemal M. High-throughput quantitative bioanalysis by LC/MS/MS. Biomed. Chromatogr. 14 (2000) 422-429
13. Sauvage F.L., Gaulier J.M., Lachatre G., and Marquet P. Pitfalls and prevention strategies for liquid chromatography-tandem mass spectrometry in the selected reaction-monitoring mode for drug analysis. Clin. Chem. 54 (2008) 1519-1527
14. Taylor P.J. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clin. Biochem. 38 (2005) 328-334
15. Maurer H.H. Current role of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Anal Bioanal. Chem. 388 (2007) 1315-1325
16. Dams R., Huestis M.A., Lambert W.E., and Murphy C.M. Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. J. Am. Soc. Mass Spectrom. 14 (2003) 1290-1294
17. Mallet C.R., Lu Z., and Mazzeo J.R. A study of ion suppression effects in electrospray ionization from mobile phase additives and solid-phase extracts. Rapid Commun. Mass Spectrom. 18 (2004) 49-58
18. Van Eeckhaut A., Lanckmans K., Sarre S., Smolders I., and Michotte Y. Validation of Bioanalytical LC-MS/MS assays: Evaluation of matrix effects. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 877 23 (2009) 2198-2207
19. Bofiglio R., King R., Olah T., and Merkle K. Rapid Commun. Mass. Spectrom. 13 17 (1999) 97